aCancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London, London, UK ...
REDWOOD CITY, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS), today announced final data from its Phase 2 open label clinical trial evaluating ...
a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a ...
a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 ...
AZD-5863 is under development for the treatment of CLDN18.2 positive advanced solid tumors including gastric cancer, adenocarcinoma of the gastroesophageal junction, pancreatic ductal adenocarcinoma, ...
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma ...
Over the next 2 months, the patient underwent radiation ... Pathologic analysis demonstrated Gleason grade 4 + 5 ductal carcinoma of the prostate. Histologic examination showed large, pleomorphic ...
1Department of Medical Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York. *Corresponding Author: Jesus D. Anampa, Montefiore Einstein Comprehensive Cancer Center, 1695 ...
Over the last decade, it has become widely accepted that there is indeed considerable overdiagnosis of both ductal carcinoma in situ ... be decreased to every 2 years to decrease overdiagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback